Study drug YL201 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign the consent form before starting
- Have advanced solid cancer confirmed by pathology (pathology test), such as small cell lung cancer, metastatic prostate cancer, esophageal cancer, or non-small cell lung cancer
- Have tried standard treatment and it didn’t work or wasn’t tolerated (for ES-SCLC in Arm C, no prior anti-cancer treatment)
- Be able to do daily life fairly well, with ECOG performance status 0 or 1
- Have at least one measurable tumor spot on scans that can be followed over time
- Have adequate blood and organ function (including bone marrow) and life expectancy of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called YL242 in people with advanced solid tumors that have not responded to prior treatment or have not been treated yet. It looks at safety, how well the drug works, and includes different groups based on cancer type and prior therapy.
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
This study tests a new drug, YL217, for people with advanced solid tumors. It is a first-in-human trial, meaning this drug has not been tested in people before, and aims to see if it is safe and how well it works.
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
This trial tests a new drug called YL202 for people with advanced solid tumors (cancers that have spread or cannot be removed). It aims to see if the drug can shrink tumors or slow cancer growth. You may be able to join if you have certain types of cancer, have not had a previous HER3 treatment, and can provide a tumor sample.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.